Surface Oncology has raised $108 million from an initial public offering to finance clinical testing of its lead cancer immunotherapy. Cambridge, MA-based Surface priced its offering of 7.2 million shares at $15 each. The company had previously planned to sell 6 million shares in the range of $13 to $15 per share. Those shares are […]
Original Article: Surface Oncology’s Upsized IPO Reels in $108M for Lead Cancer Drug